Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents

Merlevede, Jane; Droin, Nathalie; Qin, Tingting; Meldi, Kristen; Yoshida, Kenichi; Morabito, Margot; Chautard, Émilie; Auboeuf, Didier; Fenaux, Pierre; Braun, Thorsten; Itzykson, Raphaël; de Botton, Stéphane; Quesnel, Bruno; Commes, Thérèse; Jourdan, Éric; Vainchenker, William; Bernard, Olivier; Pata-Merci, Noémie; Solier, Stéphanie; Gayevskiy, Velimir; E. Dinger, Marcel; J. Cowley, Mark; Selimoglu‐Buet, Dorothée; Meyer, Vincent; Artiguenave, François; Deleuze, Jean‐François; Preudhomme, Claude; R. Stratton, Michael; B. Alexandrov, Ludmil; Padron, Eric; Ogawa, Seishi; Koscielny, Serge; E. Figueroa, María; Solary, Éric

doi:10.1038/ncomms10767

Public

Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents

Published in Nature Communications • Feb 24, 2016

Authors:

Jane Merlevede

Nathalie Droin

Tingting Qin

Abstract

The cytidine analogues azacytidine and 5-aza-2'-deoxycytidine (decitabine) are commonly used to treat myelodysplastic syndromes, with or without a myeloproliferative component. It remains unclear whether the response to these hypomethylating agents results from a cytotoxic or an epigenetic effect. I...

Subject

Decitabine

Azacitidine

Epigenetics

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!